We are a clinical-stage biopharmaceutical company pioneering a novel class of Tissue-Specific Therapeutics (TSTx) in oncology and inflammation.
In January 2023, the 17th new patient was dosed with IMX-110 to datePositive safety data enabled continued dosing of previously enrolled patients Patients undergo CT scans every 8 weeks after dosing to assess tumor response to IMX-110; clinical data expected to be released on a rolling […]
NXC-201 treatment continues to demonstrate 100% complete response rate in 6 relapsed/refractory AL amyloidosis patients to-dateClinical data published December 2022 in Clinical Cancer Research demonstrated 100% complete response rate; 100% organ response rate; Duration of Response Not Yet Reached at a median follow-up of 5.2 months, […]
Updated clinical data for NXC-201, a next-generation CAR-T for multiple myeloma and AL amyloidosis, will be presented in Rotterdam, Netherlands February 9-11, 2023LOS ANGELES, CA, Dec. 28, 2022 — Nexcella, Inc., a subsidiary of Immix Biopharma, Inc. (Nasdaq: IMMX) (“ImmixBio”, “Company”, “We” or “Us”) today announced […]
In The News
Published: Jan. 19, 2022 at 8:09 a.m. ET By Chris Wack Immix Biopharma Inc. said it saw positive interim clinical trial safety data demonstrating 100% completion of IMX-110 planned treatment cycles in its ongoing Phase 1b/2a clinical trial. The company said that historically, 43% to 67% […]
Jan. 19, 2022 9:13 AM ET Immix Biopharma, Inc. (IMMX) By: Dulan Lokuwithana, SA News Editor – Immix Biopharma (NASDAQ:IMMX) is trading ~3.6% higher after announcing 100% completion of planned treatment cycles in an ongoing Phase 1b/2a clinical trial for IMX-110, its candidate for soft tissue […]
January 4, 2022Kristi Rosa The FDA has granted a rare pediatric disease designation to IMX-110 for the treatment of rhabdomyosarcoma. The FDA has granted a rare pediatric disease designation (RPDD) to IMX-110 for the treatment of rhabdomyosarcoma, according to an announcement from Immix Biopharma, Inc., the […]
Pre-market Movers: IMMX… ContributorRTTNews.com RTTNews PublishedJan 4, 2022 7:33AM EST (RTTNews) – The following are some of the stocks making big moves in Tuesday’s pre-market trading (as of 07.20 A.M. ET). In the Green Immix Biopharma, Inc. (IMMX) is up over 18% at $6.85… Original Article […]
EXCLUSIVE: Immix CEO On ‘Benzinga Live’ Adam Eckert , Benzinga Staff Writer January 03, 2022 3:05pm Immix Biopharma Inc IMMX +62.36% stock is soaring Monday after the U.S. Food and Drug Administration granted Rare Pediatric Disease designation for IMX-110 for the treatment of rhabdomyosarcoma, a life-threatening […]
Reuters January 3, 2022 9:40 AM PST Reuters** Immix Biopharma Inc (IMMX.O): up 109.3% BUZZ-Immix Biopharma jumps on rare-disease tag for pediatric cancer drug Original Article Link
Jan. 03, 2022 8:46 AM ET Immix Biopharma, Inc. (IMMX) By: Dulan Lokuwithana, SA News Editor – Immix Biopharma (NASDAQ:IMMX) has jumped ~56.7% in the pre-market on above average volume after the company announced that the FDA granted the Rare Pediatric Disease (RPD) designation for IMX-110, […]
Published: Jan. 3, 2022 at 12:03 p.m. ETBy Colin Kellaher Shares of Immix Biopharma Inc. more than doubled on Monday after the biopharmaceutical company’s lead product candidate received rare-pediatric-disease designation from the U.S. Food and Drug Administration. The Los Angeles company said the designation covers IMX-110 […]
Seeking Alpha / Avisol Capital Partners Sep. 28, 2021 2:12 PM ET Immix Biopharma, Inc. (IMMX) Summary Immix Biopharma is developing Tissue-Specific Therapeutics in oncology and inflammation with a Tumor Micro-Environment Normalization technology.The Company’s lead candidate has shown promising results in ongoing Phase 1b/2a trials.The Company […]
Currently, there are no future events scheduled. Please check back soon.